Xhance FDA Approval History
FDA Approved: Yes (First approved September 18, 2017)
Brand name: Xhance
Generic name: fluticasone propionate
Dosage form: Nasal Spray
Previous Name: OPN-375
Company: Optinose US, Inc.
Treatment for: Nasal Polyps
Xhance (fluticasone propionate) is a topical nasal corticosteroid indicated for the treatment of nasal polyps.
Development timeline for Xhance
|Sep 19, 2017||Approval Optinose Announces FDA Approval of Xhance (fluticasone propionate) Nasal Spray for the Treatment of Nasal Polyps|
|Jan 31, 2017||OptiNose Announces FDA Acceptance for Filing of the New Drug Application for OPN-375|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.